ISPO

Risk Assessment, Part 2

Genetic polymorphisms of phase I and II metabolizing enzymes and susceptibility to esophageal adenocarcinoma.

Z Zheng, MD, , KA MacDonald, , D Chiasson, BSc, , JR Guernsey, PhD, , DL Guernsey, PhD, , DC Riddell, MD, , J McLaughlin, PhD, , AG Casson, FRCSC,

Lymph node staging of esophageal carcinoma by positron emission tomography using both C11-choline and F18-fluorodeoxyglucose

T Hara, MD, PhD, O Kobori, MD, PhD, Y Kirihara, MD, N Kosaka, MD

Cancer risk in non-transplanted and transplanted cystic fibrosis patients

P Maisonneuve Ing , SC FitzSimmons PhD , JP Neglia MD , P Campbell PhD , AB Lowenfels MD

The risk of carcinogenesis and optimization in radiotherapy

J.J. Broerse MD PhD, C.F. Hollander, J.T.M. Jansen, J. Zoetelief

Effect of steroid hormones and growth factors on the expression of cadherins and prostatic tissue specific proteins in the prostatic carcinoma cell lines.

JD Dulinska, PhD

Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma

C Giannini, MD, PhD , D Hebrink , BW Scheithauer, MD , AP Dei Tos, MD and CD James, PhD

An evaluation of cultural beliefs and values among high-risk african american women

C Hughes